Qiu C, et al. - Investigators examined 3,552 candidates to evaluate the outcome of baricitinib on low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C) levels and cardiovascular risk. Baricitinib induced a stable dose-response increase in LDL-C and HDL-C levels. They did not find significant differences in the pooled risk ratios of major cardiovascular events and cardiovascular risk scores across the population.